ZA985137B - Compositions for the treatment and prevention of arterial thrombosis and use of an inhibitor of factor Xa alone and/or in combination with an anti-platelet aggregation agent - Google Patents

Compositions for the treatment and prevention of arterial thrombosis and use of an inhibitor of factor Xa alone and/or in combination with an anti-platelet aggregation agent

Info

Publication number
ZA985137B
ZA985137B ZA985137A ZA985137A ZA985137B ZA 985137 B ZA985137 B ZA 985137B ZA 985137 A ZA985137 A ZA 985137A ZA 985137 A ZA985137 A ZA 985137A ZA 985137 B ZA985137 B ZA 985137B
Authority
ZA
South Africa
Prior art keywords
inhibitor
prevention
alone
compositions
factor
Prior art date
Application number
ZA985137A
Other languages
English (en)
Inventor
Andre Bernat
Jean Marc Herbert
Maurice Petitou
Ronald Van Amsterdam
Original Assignee
Sanofi Synthelabo
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Akzo Nobel Nv filed Critical Sanofi Synthelabo
Publication of ZA985137B publication Critical patent/ZA985137B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA985137A 1997-06-13 1998-06-12 Compositions for the treatment and prevention of arterial thrombosis and use of an inhibitor of factor Xa alone and/or in combination with an anti-platelet aggregation agent ZA985137B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9707368A FR2764511B1 (fr) 1997-06-13 1997-06-13 Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Publications (1)

Publication Number Publication Date
ZA985137B true ZA985137B (en) 1999-01-07

Family

ID=9507960

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985137A ZA985137B (en) 1997-06-13 1998-06-12 Compositions for the treatment and prevention of arterial thrombosis and use of an inhibitor of factor Xa alone and/or in combination with an anti-platelet aggregation agent

Country Status (42)

Country Link
US (2) US6541488B1 (cs)
EP (1) EP0986376B1 (cs)
JP (1) JP3988803B2 (cs)
KR (1) KR100598451B1 (cs)
CN (1) CN1253150C (cs)
AR (1) AR012247A1 (cs)
AT (1) ATE384528T1 (cs)
AU (1) AU728826B2 (cs)
BR (1) BR9810520A (cs)
CA (1) CA2293415C (cs)
CO (1) CO4940476A1 (cs)
CY (1) CY1107912T1 (cs)
CZ (1) CZ299518B6 (cs)
DE (1) DE69839046T2 (cs)
DK (1) DK0986376T3 (cs)
DZ (1) DZ2512A1 (cs)
EE (1) EE04737B1 (cs)
ES (1) ES2299209T3 (cs)
FR (1) FR2764511B1 (cs)
GT (1) GT199800171A (cs)
HR (1) HRP980322B1 (cs)
HU (1) HU227956B1 (cs)
ID (1) ID29309A (cs)
IL (1) IL133452A (cs)
IS (1) IS2619B (cs)
ME (1) ME00685B (cs)
MY (1) MY124648A (cs)
NO (1) NO323739B1 (cs)
NZ (1) NZ501452A (cs)
PL (1) PL193405B1 (cs)
PT (1) PT986376E (cs)
RS (1) RS49902B (cs)
RU (1) RU2212886C2 (cs)
SA (1) SA98190552B1 (cs)
SI (1) SI0986376T1 (cs)
SK (1) SK286311B6 (cs)
TR (1) TR199903087T2 (cs)
TW (1) TW565442B (cs)
UA (1) UA70919C2 (cs)
UY (1) UY25044A1 (cs)
WO (1) WO1998056365A1 (cs)
ZA (1) ZA985137B (cs)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
JP2002536411A (ja) 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー Ｘａ因子のラクタム系阻害剤および方法
FR2793687B1 (fr) * 1999-04-26 2001-08-24 Sanofi Sa Nouvelle composition injectable d'un anticoagulant
FR2800074B1 (fr) * 1999-10-22 2001-12-21 Aventis Pharma Sa Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US6756208B2 (en) 2001-02-28 2004-06-29 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
UA80399C2 (en) * 2001-11-13 2007-09-25 Glaxo Group Ltd Use of specific dose of fondaparinux sodium for the treatment of acs
AU2003270861A1 (en) 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
EP1564213A4 (en) * 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION AND USE THEREOF
RU2245162C2 (ru) * 2003-01-04 2005-01-27 Козлов Владимир Александрович Способ терапии инфаркта миокарда
WO2005027896A1 (ja) * 2003-09-19 2005-03-31 Kissei Pharmaceutical Co., Ltd. 併用医薬
WO2005087266A1 (en) * 2004-03-05 2005-09-22 Vddi Pharmaceuticals Combination therapy for inhibition of platelet aggregation
CA2553434C (en) * 2004-04-23 2012-08-07 Sumitomo Electric Industries, Ltd. Coding method for motion-image data, decoding method, terminal equipment executing these, and two-way interactive system
TWI396686B (zh) * 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5557410B2 (ja) * 2004-07-13 2014-07-23 第一三共株式会社 経口投与による血栓・塞栓の予防治療剤
US20070105825A1 (en) * 2004-09-16 2007-05-10 Yuji Hoyano Concurrent drugs
JP2009511544A (ja) * 2005-10-10 2009-03-19 ナームローゼ・フエンノートチヤツプ・オルガノン 抗血栓化合物
CA2735983A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
CN105561310B (zh) * 2014-10-30 2019-03-19 成都百裕制药股份有限公司 一种含有银杏内酯B和Xa因子抑制剂的药物组合物及其制备方法和用途
CN106860868B (zh) * 2015-12-11 2019-11-22 北京百奥药业有限责任公司 沙班类药物与蚓激酶的药物组合物、制剂及其应用
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE419871B (sv) * 1975-12-01 1981-08-31 Pharmacia Ab Sett att bestemma aktiviteten hos faktor xa-inhibitor i blod
DE3038163A1 (de) * 1980-10-09 1982-05-06 Boehringer Mannheim Gmbh, 6800 Mannheim Thrombininhibitor, seine herstellung und verwendung
FR2548189B1 (fr) * 1983-07-01 1986-04-11 Choay Sa Nouveaux produits contenant des oligosaccharides, leur preparation et leurs applications biologiques et biochimiques
RU2045264C1 (ru) * 1983-12-15 1995-10-10 Белорусский научно-исследовательский институт кардиологии Антиагрегационное средство
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
FR2728901B1 (fr) * 1994-12-28 1997-03-28 Sanofi Sa Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
JP4498471B2 (ja) 1996-11-27 2010-07-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド 抗―Ｘａ活性を有する化合物及び血小板凝集拮抗剤化合物を含有する製薬組成物
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire

Also Published As

Publication number Publication date
AU728826B2 (en) 2001-01-18
ATE384528T1 (de) 2008-02-15
HUP0002175A1 (hu) 2000-11-28
UA70919C2 (uk) 2004-11-15
EP0986376A1 (fr) 2000-03-22
TW565442B (en) 2003-12-11
US20040092477A1 (en) 2004-05-13
ME00685B (me) 2008-08-07
DE69839046D1 (de) 2008-03-13
FR2764511B1 (fr) 2000-09-08
SA98190552B1 (ar) 2006-09-09
NO996137L (no) 2000-02-14
AU7924698A (en) 1998-12-30
EE9900574A (et) 2000-08-15
JP2002504110A (ja) 2002-02-05
CN1253150C (zh) 2006-04-26
NO996137D0 (no) 1999-12-10
KR100598451B1 (ko) 2006-07-10
HK1032750A1 (en) 2001-08-03
HUP0002175A3 (en) 2003-05-28
BR9810520A (pt) 2000-09-19
SI0986376T1 (sl) 2008-06-30
PT986376E (pt) 2008-04-01
RS49902B (sr) 2008-08-07
DK0986376T3 (da) 2008-05-13
IS5280A (is) 1999-11-30
AR012247A1 (es) 2000-09-27
CZ446099A3 (cs) 2000-04-12
MY124648A (en) 2006-06-30
EP0986376B1 (fr) 2008-01-23
HU227956B1 (en) 2012-07-30
IS2619B (is) 2010-05-15
HRP980322A2 (en) 1999-04-30
UY25044A1 (es) 2000-10-31
CY1107912T1 (el) 2013-09-04
IL133452A (en) 2004-09-27
NO323739B1 (no) 2007-07-02
NZ501452A (en) 2002-06-28
ES2299209T3 (es) 2008-05-16
DE69839046T2 (de) 2009-01-15
DZ2512A1 (fr) 2003-02-01
CA2293415A1 (en) 1998-12-17
KR20010013690A (ko) 2001-02-26
YU63699A (sh) 2002-06-19
ID29309A (id) 2001-08-16
IL133452A0 (en) 2001-04-30
CA2293415C (en) 2011-08-09
CN1274281A (zh) 2000-11-22
RU2212886C2 (ru) 2003-09-27
JP3988803B2 (ja) 2007-10-10
PL337288A1 (en) 2000-08-14
CO4940476A1 (es) 2000-07-24
SK286311B6 (en) 2008-07-07
HRP980322B1 (en) 2003-12-31
TR199903087T2 (xx) 2000-05-22
WO1998056365A1 (fr) 1998-12-17
FR2764511A1 (fr) 1998-12-18
PL193405B1 (pl) 2007-02-28
GT199800171A (es) 2000-04-21
US6541488B1 (en) 2003-04-01
EE04737B1 (et) 2006-12-15
CZ299518B6 (cs) 2008-08-20
SK170999A3 (en) 2000-07-11

Similar Documents

Publication Publication Date Title
ZA985137B (en) Compositions for the treatment and prevention of arterial thrombosis and use of an inhibitor of factor Xa alone and/or in combination with an anti-platelet aggregation agent
NZ297118A (en) Antithrombotic formulation; comprises thrombin inhibitor and one or more absorption enhancing agents
SG55368A1 (en) Abrasive composition and use of the same
HUP0002493A3 (en) Use of colchinol derivatives as vascular damaging agents and certain new compounds
FI970920L (fi) Trifenyylietyleenejä käytettäväksi osteoporoosin ehkäisyyn ja hoitoon
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
IL134113A0 (en) Use of lactobacillus for reduction of the fibrinogen level in blood
IL160475A0 (en) Combination products of aryl-substituted propanolamine derivatives with other active ingredients and the use thereof
EP1076547A4 (en) ARABINOGALACTANE DERIVATIVES AND COMPOSITIONS CONTAINING THEM
HUP0104844A3 (en) Anticancer combination compositions containing mitoic inhibitor and mek inhibitor and their use
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
IL120302A0 (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
EP1194150A4 (en) USE OF NITROXIDES TO Heal Wounds And To Prevent Radiation Damage To Skin
GB9612628D0 (en) The use of TCET in the prophylaxis and treatment of allergies
GB9816234D0 (en) Compounds for use in the treatment of inflammation
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
ZA981781B (en) The use of levobupivacaine in treating migraine
HUP0201605A2 (en) Oral composition containing perlite and use of the perlite as cleaning agent in such compositions
SI0964884T1 (sl) Azeotropni ali psevdo-azeotropni sestavki in uporaba teh sestavkov
HUP0302738A3 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
GB2337518B (en) Dissolution inhibitor of chemically amplified photoresist and chemically amplified photoresist composition containing the same
EP0893123A4 (en) MEANS OF PREVENTIVE AND CURATIVE TREATMENT OF CONDITIONS RELATED TO DIFFERENT FORMS OF AGING OF THE ORGANISM
IL127350A0 (en) Combinations comprising VX478 zidovudine and/or 1592U89 for use in the treatment of HIV
AU2212699A (en) Use of 8-cl-camp in prevention of restenosis of arterial walls